RESHAPE-HF2:MitraClip治疗心衰合并中重度功能性二尖瓣反流患者的住院结局
RESHAPE-HF2试验预设分析显示,在症状性心衰合并中重度功能性二尖瓣反流患者中,与对照组相比,MitraClip行二尖瓣经导管缘对缘修复可降低24个月心血管死亡或心衰住院首次事件风险(HR 0.65),并减少因死亡或心衰住院损失的天数,近期有心衰住院史者获益更显著。
要点
- M-TEER降低24个月心血管死亡或心衰住院首次事件风险(HR 0.65;95%CI 0.49-0.85;P=0.002)。
- M-TEER减少因死亡或心衰住院损失的天数(13.9% vs 17.4%;P<0.0001)。
- 随机前12个月内有心衰住院史者从M-TEER获益更显著(交互P=0.03)。
核心结论
- 在症状性心衰合并中重度功能性二尖瓣反流患者中,除最佳指南导向药物治疗外,应考虑更广泛地应用M-TEER,尤其对近期有心衰住院史者。
研究设计与样本
- RESHAPE-HF2为随机试验,纳入症状性心衰合并中重度功能性二尖瓣反流患者(平均有效反流口面积0.25 cm2;14%>0.40 cm2,23%<0.20 cm2),本报告为预设的住院率分析及随机前12个月内有心衰住院史亚组(n=333)分析。
主要发现
- 24个月时,M-TEER组心血管死亡或心衰住院首次事件时间(HR 0.65;95%CI 0.49-0.85;P=0.002)、复发性心血管住院率(RR 0.75;95%CI 0.57-0.99;P=0.046)、复发性心血管住院与全因死亡复合率(RR 0.74;95%CI 0.57-0.95;P=0.017)及复发性心血管死亡与心血管住院复合率(RR 0.76;95%CI 0.58-0.99;P=0.040)均低于对照组。
- M-TEER组全因复发性住院RR为0.82(95%CI 0.63-1.07;P=0.15)。
- M-TEER组因死亡或心衰住院损失的天数更少(占随访时间13.9%[95%CI 13.0%-14.8%] vs 17.4%[95%CI 16.4%-18.4%];P<0.0001;总损失天数1,067 vs 1,776;P<0.0001)。
- M-TEER组在30天及6、12、24个月随访时NYHA功能分级更优(P<0.0001)。
- 随机前有心衰住院史与更差结局相关,且M-TEER对复发性心衰住院与心血管死亡复合率(交互P=0.03)及24个月内复发性心衰住院(交互P=0.06)的获益更大。
临床怎么用
- 对症状性心衰合并中重度功能性二尖瓣反流患者,在最佳指南导向药物治疗基础上可考虑应用M-TEER以降低心衰住院和心血管死亡风险。
- 近期有心衰住院史的患者可能从M-TEER中获得更大获益,临床决策时可优先考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For patients with functional mitral regurgitation (FMR) and symptomatic heart failure (HF), randomized trials of mitral transcatheter edge-to-edge repair (M-TEER) have produced conflicting results. OBJECTIVES: This study sought to assess the impact of M-TEER on hospitalization rates, and explore the effects of M-TEER on patients who did or did not have a history of recent HF hospitalizations before undergoing M-TEER. METHODS: RESHAPE-HF2 (Randomized Investigation of the MitraClip Device in Heart Failure: 2nd Trial in Patients with Clinically Significant Functional Mitral Regurgitation) included patients with symptomatic HF and moderate to severe FMR (mean effective regurgitant orifice area 0.25 cm2; 14% >0.40 cm2, 23% <0.20 cm2) and showed that M-TEER reduced recurrent HF hospitalizations with and without the addition of cardiovascular (CV) death and improved quality of life. We now report the results of prespecified analyses on hospitalization rates and for the subgroup of patients (n = 333) with a HF hospitalization in the 12 months before randomization. RESULTS: At 24 months, the time to first event of CV death or HF hospitalization (HR: 0.65; 95% CI: 0.49-0.85; P = 0.002), the rate of recurrent CV hospitalizations (rate ratio [RR]: 0.75; 95% CI: 0.57-0.99; P = 0.046), the composite rate of recurrent CV hospitalizations and all-cause mortality (RR: 0.74; 95% CI: 0.57-0.95; P = 0.017), and of recurrent CV death and CV hospitalizations (RR: 0.76; 95% CI: 0.58-0.99; P = 0.040), were all lower in the M-TEER group. The RR of recurrent hospitalizations for any cause was 0.82 (95% CI: 0.63-1.07; P = 0.15) for patients in the M-TEER group vs control group patients. Patients randomized to M-TEER lost fewer days due to death or HF hospitalization (13.9% [95% CI: 13.0%-14.8%] vs 17.4% [95% CI: 16.4%-18.4%] of follow-up time; P < 0.0001, and 1,067 vs 1,776 total days lost; P < 0.0001). Patients randomized to M-TEER also had better NYHA functional class at 30 days and at 6, 12, and 24 months of follow-up (P < 0.0001). A history of HF hospitalizations before randomization was associated with worse outcomes and greater benefit with M-TEER on the rate of the composite of recurrent HF hospitalizations and CV death (Pinteraction = 0.03) and of recurrent HF hospitalizations within 24 months (Pinteraction = 0.06). CONCLUSIONS: These results indicate that a broader application of M-TEER in addition to optimal guideline-directed medical therapy should be considered among patients with symptomatic HF and moderate to severe FMR, particularly in those with a history of a recent hospitalization for HF.
引用
- Ponikowski P, Friede T, von Bardeleben RS, et al. Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2. J Am Coll Cardiol. 2024. PMID: 39217574. doi:10.1016/j.jacc.2024.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。